Senseonics posted Q4 2025 revenue of $14.3 million, up 72% from $8.3 million last year, driven by U.S. sales of $12.1 million. Net loss widened to $20.8 million ($0.46 per share) as selling, general and administrative expenses rose on direct-to-consumer marketing investments.

For full year 2025, revenue reached $35.3 million, a 57% increase year-over-year, with U.S. revenue of $27.9 million and international sales of $7.4 million. Gross profit improved to $15.8 million from $0.5 million in 2024 due to favorable margins on the 365-day product and lower fixed manufacturing costs.

The company secured CE Mark approval for commercialization of the Eversense 365 continuous glucose monitoring system in Europe and launched its first automated insulin delivery integration with twiist in the U.S. It also expanded its Eon Care inserter network to 60 providers performing 24% of all U.S. insertions.

Senseonics received FDA IDE approval to begin a pivotal trial for the self-powered Gemini sensor, enrolling the first patients and targeting completion in the second half of 2026. Management plans to expand compatibility with additional AID systems and drive further patient growth through DTC marketing.